DOCSLIB.ORG

The Magazine You Can Count On

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
The Magazine You Can Count On EST.1977 1978 1979 1980 1981 www.pharmtech.com 1982 1983 1984 1985 1986 1987 1988 1989 1990 1991 1992 1993 1994 1995 1996 THE MAGAZINE 1997 YOU CAN COUNT ON 1998 MANUFACTURING/PROCESSING EQUIPMENT 1999 OUTSOURCING 2000 COMPLIANCE & VALIDATION CHEMICALS 2001 EXCIPIENTS AND APIs 2002 DRUG DELIVERY ASEPTIC/STERILE PROCESSING 2003 LAB EQUIPMENT 2004 PACKAGING 2005 2006 MEDIA PLANNER CALENDAR AND RATES INSIDE The PharmTech Brand Print-based Marketing Pharmaceutical Technology DISPLAY ADVERTISING The foundation of any B-to-B marketing program, print advertising allows offers Marketing and you to touch 38,600 BPA-Qualified subscribers* with your brand or product message. Build your marketing plan around the message conveyed in your Brand Managers an array print ad and utilize other channels to further reinforce your message. of products geared to CUSTOM PUBLISHING Work with us to write and design a custom white paper or article create deep penetration into published as an advertorial. Material for this white paper can be gathered from events such as a reader roundtable or Webinar offered our highly targeted audience. by Pharm Tech and delivered through print, email and web-based channels that incorporate lead generation mechanisms. Make the most of your marketing INSERT efforts by participating A unique way to deliver white papers, brochures, or any other collateral material to our readers. in a tailored program. POLYBAG Our highly trained sales Talk about premium placement! Send your printed piece as a ride-along, and readers will get the message as soon as the issue hits their desks. consultants will utilize mediums POST–IT NOTE A unique way to send your message to our readers, Post–It Notes serve as that fit your specific needs. front cover reminders about your brand. Use Post–Its to call out your ads in the issue, or run 6 or 12 Post–It Notes for a truly extraordinary campaign. BUSINESS REPLY CARD An efficient and effective direct response medium, BRCs can be used to promote a contest or simply to provide our readers with a distinct opportunity to contact you for more information. DIRECT MAIL Planning a direct mail campaign to reinforce your ad message? Rent our list to ensure your marketing material reaches your most important audience. COVER TIP Have a special offer, new product announcement or just want to call attention to your company’s products? Cover tips are a great way to get noticed and are much more cost effective than mailing to that same number of subscribers. Pharmaceutical Technology's authoritative reputation and powerful brand recognition within the pharmaceutical development & manufacturing marketplace will help you establish and maintain your own strong brand among pharma industry decision makers. A circulation of 38,600 BPA-qualified subscribers* and unmatched peer written and reviewed editorial make Pharmaceutical Technology an invaluable resource within top pharma companies, as well as small, specialty and biotech pharma companies spending billions each year on pharmaceutical development and manufacturing. * BPA June 2005 Statement Web-based Marketing E-NEWSLETTER ePT is a weekly newsletter offering unique opportunities to surround your advertisement with content relevant to your brand, and route buyers to a page on your site specific to your message. E-ZINE PT Electronic, delivered monthly to 60,000+^ readers, offers unique content, increased connectivity, and deeper market penetration. WEBINAR Work with us to create an on-line event that will help you address key industry issues among the people who are critical to the industry. E-MMERCIALS Another dynamic way to send your marketing message to our audience. Capture the attention of readers with this exciting flash presentation tool. Deliver your E-mmercial via a targeted email, post it on our site, and use it in your own site, on sales calls and at your trade show booth. MARKETPULSE Allow us to deliver the answers to your most pressing questions with a customized on-line survey of our readers. PRODUCTBLAST You provide the links and the message, and we provide the community. Blast your product offerings, on-line catalogue, or newest product announcements with ProductBlast. Sent to select readers, based on your demographic target, ProductBlast is an effective way to spread the word about your products, and directly link readers to them. WEB SITE There are many opportunities on pharmtech.com. Banners, buttons, skyscrapers, big-box ads, product spotlights, and QuickPolls all provide unique ways for sellers to connect with buyers online. E-NTERVIEWS Extend your trade show message! You provide a spokesperson to deliver your product message in a Q&A format. We provide the camera crew, edit the footage and produce a 5 minute video for email distribution the next morning, to readers in your demographic selects. Also, available via links in the email and on the web site. E-SHOW DAILIES Deliver news from your conference or trade show to thousands in your industry—— even if they're not at the event! We’ll send a reporter to cover your conference who will produce an E-Show Daily hosted on our site. An email will be pushed the next morning, to readers in your demographic selects, and available on the site with links directing users to show coverage. E-CARD DECK E-Card Deck——an electronic medium where advertisers successfully interact with purchasers——is an e-business reply card that provides the functionality that today’s decision makers require by using state-of-the-art technology to relay a marketing message with added benefits such as: • Push technology to a select group at an optimal time • Trackable results relating the effectiveness of your ad • Speed of delivery • Cost effectiveness and high ROI compared with Immediate delivery results traditional direct mail campaigns and limited mailing • list capabilities • Customer-friendly response capability via a link back to a page or a form on your website Face-to-Face Marketing PHARMACEUTICAL CONFERENCES Our branded conferences bring Pharmaceutical Technology’s audience and our expert content to life. Partner with PharmTech to make contact with the most influential professionals in your market. SINGLE-SPONSOR EVENT Do you have an idea for a conference but lack the resources to bring your target community together? Partner with us to launch a conference focused on your objectives. READER ROUNDTABLE You provide the topic, and we will provide a roundtable of readers selected from your target demographic, and facilitate your meeting. Think of it as your very own expert focus group. ^ Publisher’s Own Data The PharmTech Audience: Circulation Over the years, Pharmaceutical Technology has built and grown a circulation of 38,600 BPA-qualified subscribers*. We’ve cornered the market on R&D, QA/QC, Production/Manufacturing/Engineering and related job functions at top Pharma and Biotech manufacturing companies.** REACH KEY DECISION-MAKERS THROUGHOUT THE DEVELOPMENT AND MANUFACTURING PROCESS: 5.1% Universities (1,986) BUSINESS AND INDUSTRY* 3.5% Consultant to the Pharmaceutical Industry (1,363) 3.3% Drug Delivery Devices & Instrumentation Manufacturing (1,265) 82.2% 2.6% Government (1,009) Pharmaceutical & 1.6% Architecture/Engineering/Construction (615) Biopharmaceutical Manufacturing/ Contract Research/Analytical Services/ 1.5% Other Paid Circulation: Subscriptions (593) Specialty Chemicals, Bulk Products & 0.1% Others Allied to the Field (25) Raw Material Producers (31,744) IN A VARIETY OF JOB FUNCTIONS * Engineering (4,428) 11.5% 33.1% Production Manufacturing (3,688) 9.6% Research & Development (12,758) Corporate Management (2,450) 6.4% Technical/Analytical Service/Support (1,446) 3.7% Marketing and Sales Management (1,440) 3.7% Regulatory Affairs (1,288) 3.3% Lab Management (1,227) 3.2% Other Functions Allied to the Field (1,095) 2.8% Project Management (857) 2.2% Information Technology (431) 1.1% Materials Manufacturing/Purchasing (278) 0.7% 18.7% Quality Control/Assurance Validation (7,214) * BPA June 2005 Statement ** Publisher’s Own Data PHARMACEUTICAL TECHNOLOGY DELIVERS THE LARGEST AVERAGE QUALIFIED CIRCULATION WITH THE HIGHEST PERCENTAGE OF DIRECT REQUEST SUBSCRIPTIONS* uring uring act act t t s s ulation c ulation eque eque c ech Manuf ied Cir ech Manuf t t ar ect R io ar e ect R io ar ar e ied Cir QC QC ar ar e e e e A/ A/ ee Y ee Y al Dir Q Q o Y o Y al Dir t / / hr t w w hr o o age Qualif &D f One Y f T f T f T al Qualif &D f One Y f T f T f T t er o v T A # Pharma/B % Pharma/B # R % R # o % o # o % o # o % o # o % o Pharmaceutical 38,600 35,280 27,986 72.5% 19,972 51.7% 31,992 82.9% 6,608 17.1% 0 0.0% 32,999 85.5% Technology American 12,406 12,616 5,891** 47.4%** 5,304 42.8% 6,119 49.4% 2,336 18.8% 3,951 31.8% 12,379 99.8% Pharmaceutical Outsourcing American 30,266 30,205 15,513** 51.2%** 11,162 36.9% 19,497 64.4% 4,661 15.4% 6,108 20.2% 20,609 68.1% Pharmaceutical Review Contract Pharma 20,000 20,003 9,856 49.1% 6,724 33.6% 15,071 75.4% 4,562 22.8% 367 1.8% 19,982 99.9% Drug Delivery Not Technology Audited Pharmaceutical Not Formulation Audited Pharmaceutical 25,050 25,041 18,296** 73%** 7,210 28.8% Not Not Not Not Not Not Not Not Manufacturing Reported Reported Reported Reported Reported Reported Reported Reported Pharmaceutical 31,020 31,016 24,374*** 78.7%*** 12,970 41.8% 24,900 80.3% 6,120 19.7% 0 0.0% 26,538 85.6% Processing Tablets & Capsules 9,550 9,649 7,748**** 81.1%**** 2,886 30.0% 8,727 91.4% 823 8.6% 0 0.0% 6,724 70.4% REACH INDUSTRY LEADERS AT TOP COMPANIES ^ [# of Subscribers] Pfizer 1548 Alcon
Load more

Recommended publications
  • Orange Book Cumulative Supplement 7 July 2006
    CUMULATIVE SUPPLEMENT 07 July 2006 APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS 26th EDITION Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research Office of Generic Drugs 2006 Prepared By Office of Generic Drugs Center for Drug Evaluation and Research Food and Drug Administration APPROVED DRUG PRODUCTS with THERAPEUTIC EQUIVALENCE EVALUATIONS 26th EDITION Cumulative Supplement 07 July 2006 CONTENTS PAGE 1.0 INTRODUCTION ........................................................................................................................................ iii 1.1 How to use the Cumulative Supplement ........................................................................................... iii 1.2 Applicant Name Changes.................................................................................................................. iv 1.3 Availability of the Edition ................................................................................................................... vi 1.4 Report of Counts for the Prescription Drug Product List ................................................................... vi 1.5 Zocor (simvastatin) Patent Relisting.................................................................................................viii 1.6 Cumulative Supplement Legend ....................................................................................................... vi DRUG PRODUCT LISTS Prescription Drug Product List ......................................................................................................
    [Show full text]
  • 9894 Pharma Tech Media Planner V6 2007
    www.pharmtech.com years 1977– 2007 30ANNIVERSARY CELEBRATING 30 YEARS AS THE 2007 INDUSTRY’S MOST AUTHORITATIVE SOURCE Media Planner years 1977–2007 ANNIVERSARY years 1977–2007 ANNIVERSARY THE PHARMACEUTICAL TECHNOLOGY BRAND PUBLISHER’S STATEMENT Pharmaceutical Technology’s authoritative reputation and powerful brand recognition within the pharmaceutical/biopharmaceutical development & manufacturing marketplace will help you establish and maintain your own strong brand among pharma industry decision makers. A circulation of 38,667 BPA-qualified subscribers* and unmatched peer written and reviewed editorial make Pharmaceutical Technology an invaluable resource within top pharma companies, as well as small, specialty and biotech pharma companies spending billions each year on pharmaceutical development and manufacturing. Please celebrate with us as Pharmaceutical Technology marks its 30th Anniversary as the industry leader. —Michael Tracey, Publisher % 90 of readers rated Pharmaceutical Technology as important or very important to them as a professionalˆ EDITORIAL MISSION Pharmaceutical Technology publishes authoritative, reliable, and timely peer-reviewed research and expert analyses for scientists, engineers, technicians, and managers engaged in process development, manufacturing, formulation, analytical technology, packaging and regulatory compliance in the pharmaceutical and biotechnology industries. —Douglas McCormick, Editor in chief www.pharmtech.com *BPA June 2006 Statement ^2006 Readership Study Conducted by Advanstar Research
    [Show full text]
  • Audit Final Pn 5-28-04
    Appendix Radio Radio Callsign Service Licensee State Callsign Service Licensee State KA26590 IG MDOI INC TX KA96512 IG PM REALTY GROUP TX KA2774 PW OXFORD, VILLAGE OF MI KAA245 IG YELLOW & CITY CAB CO KS KA3917 IG SCRANTON TIMES PA KAD598 PW RED OAK VETERINARY CLINIC IA KA40009 IG GADSDEN, CITY OF AL KAE933 IG FOODSERVICE MANAGEMENT GROUPFL INC KA40058 IG HOUMANN, JIM:HOUMANN, CHETND KAG551 PW COOK, RICHARD L MO KA42246 IG HOUSTON FLEA MARKET INC TX KAH411 IG MIKE HOPKINS DIST CO INC TX KA42563 IG MUIRFIELD VILLAGE GOLF CLUBOH KAH535 PW CEDAR RAPIDS, CITY OF IA KA4305 IG CITY OF LOS ANGELES DEPARTMENTCA OF KAJ418WATER & POWERIG KOPSA, LEO E IA KA43600 IG SHAPLEY, CHARLES P MO KAM394 IG CROOKSTON IMPLEMENT CO INCMN KA48204 PW PRESQUE ISLE, COUNTY OF MI KAM826 IG AIRGAS SOUTHWEST INC TX KA52811 IG R & R INDUSTRIES INC MA KAM951 IG TERRA INTERNATIONAL INC IA KA53323 IG ELK RIDGE LOG INC WA KAM983 IG RAY KREBSBACH & SONS IA KA53447 PW PIERCE, TOWNSHIP OF OH KAN247 IG BROCE CONSTRUCTION CO INCKS KA53918 IG B M I INC MI KAN892 PW HIAWATHA, CITY OF KS KA61058 IG THISTLE, RONALD F MA KAO274 IG MALINE, THOMAS G NE KA62473 PW KENTUCKY, COMMONWEALTH OFKY DBA KYKAP406 EMERGENCY MANAGEMENTIG DYNEGY IT INC TX KA64283 IG SAINT MARY MEDICAL CENTERWA KAP554 IG AWARE OPERATING SERVICES TXINC KA64769 IG SOUTHERN WAREHOUSING & DISTRIBUTIONFL KAQ533 LTD PW CALIFORNIA, STATE OF CA KA65089 IG DUN & BRADSTREET NJ KAQ708 PW PENNSYLVANIA, COMMONWEALTHPA OF KA65696 IG PARSONS INFRASTRUCTURE &CA TECHNOLOGYKAR785 GROUP PW PIMA, COUNTY OF AZ KA66353 IG BALTIMORE MARINE
    [Show full text]
  • Oral Delivery Oct 06 18/1/07 20:19 Page 1
    Oral Delivery Oct 06 18/1/07 20:19 Page 1 ORAL DRUG DELIVERY WHEN YOU FIND THE HOLY GRAIL www.ondrugdelivery.com Oral Delivery Oct 06 18/1/07 20:19 Page 2 “Oral drug delivery: when you find the Holy Grail” CONTENTS This edition is one in a series of sponsored themed publications from ONdrugDelivery Ltd. Each issue focuses on a specific topic within the field of drug delivery, and contain up to eight articles contributed Introductory comment by leaders in that field. Guy Furness 3 Full contact information appears alongside each article. Contributing companies would be delighted to hear Growing sales and new opportunities for oral from interested readers directly. ONdrugDelivery fast dissolve would also be very pleased to pass on to authors, or Dr Ian Muir answer as appropriate, any queries you might have in relation to this publication or others in the series. Cardinal Health 4-6 During 2007 ONdrugDelivery will be covering the following topics: From oral drug delivery technology to proprietary February: Transdermal delivery product development April: Pulmonary delivery Dr Anand Baichwal, Thomas Sciascia, MD June: Prefilled syringes Penwest Pharmaceuticals 7-10 August: Oral drug delivery October: Delivering injectables December: Nanotechnology in drug delivery Combination oral products: the time is now! Fred H. Miller To start a FREE subscription (pdf or print) to INNERCAP Technologies 12-15 ONdrugDelivery’s sponsored series, please contact ONdrugDelivery directly (details below) Combining technologies without compromise: taste masking + ODT + modified release Steve Ellul Eurand 16-19 Oral drug delivery: the Holy Grail To find out more about how your company can Ms Bavani Shankar participate in 2007, please contact ONdrugDelivery Emisphere Technologies 20-21 directly (details below).
    [Show full text]
  • Federal Register/Vol. 77, No. 115/Thursday, June 14, 2012
    Federal Register / Vol. 77, No. 115 / Thursday, June 14, 2012 / Notices 35691 TABLE 1—LIST OF SAFETY AND EFFECTIVENESS SUMMARIES FOR APPROVED PMAS MADE AVAILABLE FROM JANUARY 1, 2012, THROUGH MARCH 31, 2012—Continued PMA No., Docket No. Applicant Trade name Approval date P060008.S046, FDA–2012–M–0210 ... Boston Scientific Corp ......................... TAXUS Liberte´ Paclitaxel-Eluting Cor- February 22, 2012. onary Stent System (Monorail and Over-The-Wire Delivery Systems). P030025.S086, FDA–2012–M–0209 ... Boston Scientific Corp ......................... TAXUS Express2 Paclitaxel-Eluting February 22, 2012. Coronary Stent System (Monorail and Over-The-Wire Delivery Sys- tems). P110023, FDA–2012–M–0221 ............ ev3, Inc ................................................ Everflex Self-Expanding Peripheral March 7, 2012. Stent System (Everflex). P070004, FDA–2012–M–0250............ Sientra, Inc.......................................... SIENTRA Silicone Gel Breast Im- March 9, 2012. plants. II. Electronic Access LOCATION: The meeting will be held at submissions. In the process of Persons with access to the Internet the FDA White Oak Campus, 10903 considering these changes, FDA has may obtain the documents at http:// New Hampshire Ave., Bldg. 31 previously made available for comment www.fda.gov/MedicalDevices/ Conference Center, Great Room 1503, versions of documents that support ProductsandMedicalProcedures/ Silver Spring, MD 20993. The following making regulatory submissions in DeviceApprovalsandClearances/ link contains public meeting attendee electronic format using the (eCTD) information as well as frequently asked PMAApprovals/default.htm and http:// specifications. These draft documents questions and answers regarding public www.fda.gov/MedicalDevices/ represented FDA’s major updates to meetings at White Oak: http:// ProductsandMedicalProcedures/ Module 1 of the eCTD based on www.fda.gov/AboutFDA/ DeviceApprovalsandClearances/ previous comments.
    [Show full text]
  • Helen Keller Helen Keller
    HELEN KELLER Prepared for USAID BHR/PVC GRANT NO. 3077 March 23, 1995 Contact Person: Louis D. Pizzarello, MD, MPH Medical Director Helen Keller International 90 Washington St. New York, NY 10006 A world leader ill blilldlless prer.:elllioIJ alld rehabilitotioll since 1915. WORLD HEADQUARTERS 90 WASHINGTO:-: STREET. NEW YORK, NEW YORK 10006 TEL (212) 943'()890 F.-\X (212) 943-1220 @ PROJECT SEE ANNUAL REPORT PROJECT SEE (Sustainable, Efficient, Eye Care) OCTOBER 1993-SEPTEMBER 1994 TABLE OF CONTENTS Executive Summary . • . • . • • . • . • . 1 I. Headquarters. • • . 3 ll. Mexico. • . • . • . .. 5 Ill. Morocco. • . • . • . • • . 11 IV. Philippines ....•..........•.......•...•...........•.•.. 18 V. Tanzania. ....... 25 Appendix I Childhood Blindness Technical Advisory Group (CBTAG) Forms and Guidelines Appendixll Procurement and Gifts-in-Kind per country Appendix III Headquarters and Field Organizational Charts Appendix IV Primary Eye Care Training Manual Draft Outline Appendix V Summary of Eye Disease Chihuahua State, Mexico Appendix VI Morocco Surgical Outcome Details Appendix VII Philippines Residency Training Map & Curriculum Appendix VIll 'fl Budget Pipeline October 1993-September 1994 •• PROJECrSEE ANNUAL REPORT OCTOBER 1993 - SEPTEMBER 1994 Executive Summm Project SEE ~ustainab1e, Efficient, Eye Care) is a major public health and blindness prevention effort undertaken by Helen Keller International. This project builds on progress attained through previous Matching Grant programs. Over the last year, Project SEE has successfully enhanced the ability of HKI field staff and Ministries of Health to deliver eye health and blindness prevention services to the people of Mexico, Morocco, Philippines and Tanzania. With the support of USAID and Helen Keller International, hundreds of thousands of families have access to services, not previously available to them, and in many cases, this service is now closer to home.
    [Show full text]
  • Department of Vermont Health Access Over-The-Counter (OTC) Drugs
    Department of Vermont Health Access Over-the-Counter (OTC) Drugs Report Date: 2/5/2020 DRUG CATEGORY BRAND / PA GENERIC DRUG DESCRIPTION NDC GENERI PRODUCT DESCRIPTION REQUIRED LABELER NAME C ACNE PRODUCTS Adapalene Gel 0.1% GALDERMA 00299491015 B DIFFERIN GEL 0.1% GALDERMA 00299491045 B DIFFERIN GEL 0.1% GALDERMA 00299492030 B DIFFERIN GEL 0.1% GALDERMA 00299492045 B DIFFERIN GEL 0.1% Benzoyl Peroxide Cloth 6% ACELLA PHARMACEUTICALS 42192016160 G BPO CLOTHS MIS 6% Benzoyl Peroxide Gel 10% RUGBY LABORATORIES 00536105656 G ACNE MEDICAT GEL 10% PERRIGO PHARMACEUTICALS 45802030801 G BENZOYL PER GEL 10% PERRIGO PHARMACEUTICALS 45802030896 G BENZOYL PER GEL 10% Benzoyl Peroxide Gel 2.5% PERRIGO PHARMACEUTICALS 45802010196 G BENZOYL PER GEL 2.5% Benzoyl Peroxide Gel 5% RUGBY LABORATORIES 00536105556 G ACNE MEDICAT GEL 5% PERRIGO PHARMACEUTICALS 45802021601 G BENZOYL PER GEL 5% PERRIGO PHARMACEUTICALS 45802021696 G BENZOYL PER GEL 5% Benzoyl Peroxide Liq 10% PERRIGO PHARMACEUTICALS 45802031801 G BENZOYL PER LIQ 10% WASH PERRIGO PHARMACEUTICALS 45802031834 G BENZOYL PER LIQ 10% WASH HARRIS PHARMACEUTICAL 67405083005 G BENZOYL PER LIQ 10% WASH HARRIS PHARMACEUTICAL 67405083008 G BENZOYL PER LIQ 10% WASH GLAXO CONSUMER HEALTHCARE L.P. 00145098505 G PANOXYL WASH LIQ 10% CROWN LABORATORIES 00316022855 G PANOXYL WASH LIQ 10% Benzoyl Peroxide Liq 4% CROWN LABORATORIES 00316022706 G PANOXYL WASH LIQ 4% GLAXO CONSUMER HEALTHCARE L.P. 00145266005 B PANOXYL-4 LIQ CREM WSH Benzoyl Peroxide Liq 5% PERRIGO PHARMACEUTICALS 45802028001 G BENZOYL PER LIQ 5%
    [Show full text]
  • ANNUAL REPORT 2007 Table of Contents
    ANNUAL REPORT 2007 table of contents _____________________________________________________PAGE _____________________________________________________2 Dedication _____________________________________________________3 Message from the Chairman and the President & CEO _____________________________________________________4 Introduction _____________________________________________________6 Our Focus _____________________________________________________10 Strategic Partnerships _____________________________________________________14 Emergency Response _____________________________________________________20 Our Partners _____________________________________________________25 Introduction and Certifi cation of Financial Statements _____________________________________________________26 Financial Statements _____________________________________________________28 Notes to the Financials _____________________________________________________34 Our Investors PHOTO (opposite page): Randy Olson, courtesy of BD In the spring of 2007, Direct Relief and a team of volunteers from the medical technology company BD worked together to improve health care for mothers and children in an underserved region in Ghana. See page 11 for their story. This report is dedicated to Dr. John Ganda July 27, 1942 – January 14, 2007 For his life-long dedication to the health and welfare of the people of Sierra Leone and his passionate resolve at the helm of the Ndegbomei Development Organization through many years of civil war. 2 Message from the Chairman and the President
    [Show full text]
  • In Re: IMPAX Laboratories, Inc. Securities Litigation 04-CV-04802
    EXHIBIT E United States Securities and Exchange Commission Washington, D .C . 2054 9 FORM 10-Q/A Amendment No . 1 (Mark One ) (X) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF TH E SECURITIES EXCHANGE ACT OF 193 4 For the quarterly period ended June 30, 2004 ------------- OR ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF TH E SECURITIES EXCHANGE ACT OF 1934 For the transition period from t o Commission file number 0-27354 Impax Laboratories, Inc . -------------------------------------------------------------------------------- (Exact name of registrant as specified in its charter) Delaware 65-0403311 ---------------------------------- ------------------- (State or other jurisdiction of (I .R .S . Employer incorporation or organization) Identification No .) 30831 Huntwood Avenue - Hayward, California 9454 4 ---------------------------------------------- ------------ (Address of principal executive offices) (Zip code) Registrant's telephone number including area code (510) 476-200 0 -------------- Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports ) and (2 ) has been subject to such filing requirements for the past 90 days . Yes X No Indicate by check mark whether registrant is an accelerated filer (as defined in Rule 12b-2 of the Act .) Yes X N o The number of shares outstanding of the registrant's common stock as o f July 30, 2004 was approximately 58,464,926 . ------------ ---------- EXPLANATORY NOTE This amendment is being filed to reflect the restatement of the Company's condensed financial statements, as discussed in Note 14 thereto, and other information related to such restated financial statements .
    [Show full text]
  • 05 Biomanufacturing Brochure Cxns.Indd
    Biomanufacturing in North Carolina MANUFACTURERS OF PHARMACEUTICALS AND DIAGNOSTICS CONTRACT MANUFACTURING SERVICE PROVIDERS Biotechnology companies throughout North Carolina are using living cells to COMPANY PRODUCTS LOCATION COMPANY SERVICES LOCATION produce medicines, vaccines, diagnostics, enzymes, amino acids, veterinary Alpharma USPD Pharmaceuticals Lincolnton Broad range of analytical and manufacturing medicines and related products that improve our lives, create jobs and boost our AaiPharma services Wilmington Banner Pharmacaps Pharmaceutical gel caps High Point economy. The making of these biological products is called biomanufacturing or Cardinal Health Analytical services Morrisville bioprocessing. Baxter Healthcare IV Systems Intravenous solutions Marion Bulk chemical synthesis, fill and finish, and DSM Pharmaceuticals aseptic filling services Greenville “North Carolina’s North Carolina is a national leader in this Bespak Drug-delivery devices Apex growing industry. Sixteen companies have Sterile solutions and emulsions for infusion and business climate, low biomanufacturing operations in North BioMerieux Diagnostic kits Durham Hospira nutrition therapy Clayton tax burden and high- Carolina, and at least 30 other companies Carolina Medical Products Ointments, powders, non-injectable solutions Farmville Development and manufacture of topical are engaged in related manufacturing of skill work force make Cytosol Ophthalmics Sterile balanced salt solutions Lenoir Harmony Labs pharmaceuticals and cosmeceuticals Landis this region
    [Show full text]
  • Nutraceuticals Pages: 278
    Freedonia Industry Study #1359 Study Publication Date: November 2000 Price: $3,700 Nutraceuticals Pages: 278 Nutraceuticals, a new study from The Freedonia Group, provides you with an in-depth analysis of major trends in the industry and the outlook for product segments and major markets -- critical information to help you with strategic planning. This brochure gives you an indication of the scope, depth and value of Freedonia's new study, Nutraceuticals. Order- ing information is included on the back page of the brochure. Brochure Table of Contents Study Highlights ......................................................................2 Table of Contents and List of Tables and Charts ..........................4 Sample Pages and Sample Tables from: Market Environment ..............................................6 Products ...............................................................7 Applications ..........................................................8 Industry Structure ..................................................9 Company Profiles ................................................ 10 List of Companies Profiled ................................... 11 Forecasting Methodology ........................................................ 12 About the Company ............................................................... 13 Advantages of Freedonia Reports ............................................. 13 About Our Customers ............................................................ 14 Other Titles From Freedonia .................................................
    [Show full text]
  • Latin America: the Answer to Drug Companies' Problems?
    PUBLIC CITIZEN HEALTH RESEARCH GROUP SIDNEY M. WOLFE, M. D., EDITOR APRIL 2001 + VOL. 17, NO . 4 Latin America: the Answer to Drug Companies' Problems? t never seems to end. Once again, While the researchers in the HIV foreign investigators registered with U.S. researchers are proposing a studies were generally government the FDA grew over five-fold in the I study in developing countries in scientists or academics who were ap­ decade of the 1990s. which poor people would receive pla­ parently committed to helping resi­ The latest scandal involves a biotech cebos instead of proven, lifesaving dents of the developing world, the new startup company in Doylestown, PA therapies. And this time, the U.S. gov­ wave of unethical research involves called Discovery Laboratories, which, ernment, in the form of the Food and the for-profit pharmaceutical industry in collaboration with Johnson & Drug Administration (FDA), is playing whose motives are far less clear. Seiz­ Johnson, manufactures an experimen­ a leading role. ing upon some of the same justifica­ tal drug called Surfaxin for the treat­ In April 1997, Public Citizen blew tions put forth by the HIV researchers ment of the often-fatal Respiratory the whistle on a set of 15 research ("they wouldn't have been treated any­ Distress Syndrome (RDS) in premature studies involving HIV -positive preg­ way"), drug companies are now invad­ infants. The drug belongs to a class nant women in which some of the ing the Third World with intent to called surfactants, which are naturally women were not given AZT, a drug conduct research that would be clearly occurring compounds that help the that had been shown to reduce dra­ unethical in the U.S.
    [Show full text]